SMS data analyses are performed in silico using various software programs; however, in silico analysis is typically regarded as a burden on wet-lab experimental microbiologists. Therefore, in this review, we present microbiologists who are unfamiliar with in silico analyses with a basic and practical SMS data analysis protocol. This protocol covers all the bioinformatics processes of the SMS analysis in terms of data preprocessing, taxonomic profiling, functional annotation, and visualization.System-wide studies of a given molecular type are referred to as "omics." These include genomics, proteomics, and metabolomics, among others. Recent biotechnological advances allow for high-throughput measurement of cellular components, and thus it becomes possible to take a snapshot of all molecules inside cells, a form of omics study. Advances in computational modeling methods also make it possible to predict cellular mechanisms from the snapshots. These technologies have opened an era of computation-based biology. Component snapshots allow the discovery of gene-phenotype relationships in diseases, microorganisms in the human body, etc. Computational models allow us to predict new outcomes, which are useful in strain design in metabolic engineering and drug discovery from protein-ligand interactions. However, as the quantity of data increases or the model becomes complicated, the process becomes less accessible to biologists. In this special issue, six protocol articles are presented as user guides in the field of computational biology.For years, spirituality and finding the meaning of life have been considered essential phenomena in the context of human existence. Zohar introduced the term spiritual intelligence (SI) in 1997, and since that time researchers have been seeking to clarify the concept. Emmons (The psychology of ultimate concerns. Guilford Press, New York, 1999) suggested that SI serves as a potentially significant construct to expand our understanding of the psychological determinants of human functioning. In recent years, several efforts to conceptualize and measure this construct have joined the body of related literature, of which King (Brighter paths to wellbeing an integrative model of human intelligence and health. Trent University Centre for Health Studies Showcase, pp 12-13, 2008) serves as one notable example. Following, evaluating, and summarizing the theoretical debate regarding the validity of a concept, as it is presented in the literature, has long been understood as a helpful way of extending scholarly dialogue. In this project, I review psychological literature relevant to the debate on the validity of SI as a psychological construct. The literature offers many examples that demonstrate a relation between SI and other phenomena that are important for human functioning-well-being in this. Results of the analysis support theoretical considerations for viewing SI as facilitating the ability to search for the meaning of life and provide directions for future study.Research on the acceptability of faith-based health promotion programs by Latino communities in the Bible Belt is limited. This study examined the needs, barriers, and facilitators related to such programs in Memphis, TN. Thirty Latino community members and ten faith leaders participated in focus groups and in-depth interviews, respectively. Health needs identified included diet, dental care, and screenings, while barriers included cost, education, lack of prevention-seeking behaviors, and need for Spanish language services. Faith leaders were aware of more health resources than community members. Despite being receptive and acknowledging the need for faith-based programs aimed at prevention and filling healthcare gaps, concerns regarding the influence of religious doctrine on health interventions were expressed by members of both groups. Faith leaders, practitioners, and community members must work together to overcome barriers related to trust and health behavior norms.Immunoglobulin E (IgE) plays a central role in allergic reactions. IgE is a dynamic molecule that is capable of undergoing large conformational changes. X-ray crystal structures of the Fc region of IgE in complex with various ligands have shown that IgE-Fc can exist in extended and various bent conformations. IgE-Fc consists of three domains Cε2, Cε3 and Cε4. While the complete NMR backbone assignments of the Cε2 and Cε3 domains have been reported previously, the Cε4 domain has not been assigned. Here, we report the complete backbone assignment of the Cε4 homodimer. Cε4 can be used as a model system to study dynamics and allostery in IgE, as both molecules exist as homodimers and exhibit similar binding properties to a number of ligands.INTRODUCTION Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies are powerful lipid-lowering drugs which have been shown to improve clinical endpoints in patients with hypercholesterolemia. However, it is not clear how effective PCSK9 monoclonal antibodies are for patients at high cardiovascular risk. Also, whether the effectiveness of PCSK9 monoclonal antibodies varies between different drug types, dosages, race, and indications for PCSK9 monoclonal antibodies remains unclear. Therefore, we used recently published studies to systematically evaluate the efficacy and safety of PCSK9 monoclonal antibodies by analyzing the lipid profiles, adverse events, and clinical endpoints in patients at high cardiovascular risk. METHODS Randomized controlled trials (RCTs) comparing PCSK9 monoclonal antibodies with placebos or active drugs in patients at high cardiovascular risk were retrieved from electronic databases from their inception until November 2019.  https://www.selleckchem.com/products/MLN-2238.html  Efficacy and safety outcomes included lowly increased risk of injection site reactions (relative risks (RR) 1.54; 95% CI 1.38-1.71; P  less then  0.001). Both alirocumab (RR 0.89; 95% CI 0.83-0.95; P  less then  0.001) and evolocumab (RR 0.86; 95% CI 0.80-0.92; P  less then  0.001) were associated with a lower risk of major cardiovascular events (MACEs), especially in secondary preventive patients (alirocumab group RR 0.88; 95% CI 0.82-0.95; P  less then  0.001; evolocumab group RR 0.86; 95% CI 0.80-0.92; P  less then  0.001). The reduction in MACEs was observed in White but not in Asian subjects. No significant reduction of all-cause mortality was found (RR 0.88; 95% CI 0.72-1.07; P = 0.182). CONCLUSION Both alirocumab and evolocumab are well tolerated and can greatly improve lipid profiles for patients at high cardiovascular risk. Both PCSK9 monoclonal antibodies significantly reduce the risk of nonfatal MACEs in patients with previous cardiovascular events, but the effect on all-cause mortality remains uncertain.